Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis

Abstract

Background: This study evaluated the role of HA as a marker of liver fi brosis in patients with hepatitis C on haemodialysis. Methods: This is a cross-sectional study in which 52 patients were divided into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classifi ed by METAVIR group scoring system. Results: Higher plasma levels were signifi cantly correlated to signifi cant liver fi brosis (METAVIR ≥ F2). In Group 1, the HA cutoff to discriminate signifi cant fi brosis was 984.8 ng/mL, with accuracy, sensitivity and specifi city of 80.8%, 83.0%, and 70.0%, respectively. In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specifi city of 74.5%, 70.0%, and 94.0%, respectively. Conclusion: HA was an accurate noninvasive marker in predicting signifi cant fi brosis in patients with hepatitis C on haemodialysis.

Infusion of human umbilical cord-derived mesenchymal stem cells effectively relieves liver cirrhosis in DEN-induced rats

“…4). These results indicated that liver fibrosis was successfully induced when rats were treated with DEN via the drinking water, which was consistent with a previous finding that liver fibrosis was induced by weekly intraperitoneal injections of DEN (20). Subsequently, the remaining 85 DEN-induced rats (except the 8 rats exhibiting serious ascites) were randomly divided into the DEN control group and 5 hUCMSCs treatment groups (Fig.…”

Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients

“…Patients with chronic viral hepatitis/liver cirrhosis B or C and ESRD treated by HD represent a special patient population because the prevalence of chronic C virus infection is between 9 and 80 % worldwide [1][2][3], and prevalence of chronic B virus infection is 1 % in USA, 9 % in Italy, and up to 15.3 % in Asia [4,5]; liver disease has a more severe evolution, particularly on account of the Abstract Purpose Serum hyaluronic acid (sHA) is studied as a noninvasive marker of liver fibrosis (F) in chronic B and C viral hepatitis in general population but less in end-stage renal disease patients undergoing hemodialysis. Methods We evaluated sHA as a noninvasive biomarker of F in a multicenter prospective, transversal, and observational study which included 52 end-stage renal disease patients with chronic B (14) and C (38) viral hepatitis (age 55.57 ± 14.46 years, dialysis vintage 132.59 ± 86.02 months).…”

Hyaluronic acid in end-stage renal disease treated by hemodialysis

“…Liver puncture biopsy, the gold standard for assessing liver fibrosis, has a higher risk of complications in hemodialysis patients: 13.2%. 4 Serum hyaluronic acid is a non-invasive marker for liver fibrosis in chronic B and C viral hepatitis in general population, but is less used in ESRD patients undergoing hemodialysis. High plasma hyaluronic acid levels have already been described in ESRD and is previously reported that the duration on hemodialysis and certain markers of chronic inflammation, such as dialysis-related amyloid, is correlated with hyaluronic acid levels.…”

“…5,6 Cytokine production may be stimulated by contact of the blood with bioincompatible dialysis membranes, and cytokines have been shown to stimulate hyaluronic acid synthesis. 4 Hyaluronic acid level is a good non-invasive marker for the differentiation of liver fibrosis stages 1, 2 and 3 in hemodialysis patients with hepatitis B and C, but its efficiency to differentiate chronic hepatitis from liver cirrhosis was not demonstrated. Hyaluronic acid has the highest clinical utility for stage 1 of liver fibrosis (clinical net benefit 0.22%) in patients with ESRD and chronic hepatitis B or C. 7 The aim of our research is to evaluate if ESRD under hemodialysis influence the serum level of hyaluronic acid in chronic viral liver diseases in Romanian patients.…”